Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396149 | 0.98 | MAPT (0.40) | MAPTSLC22A16CES2CES1CYP1A2 | |
| Iodide SCHEMBL1157375 | 0.96 | MAPT (0.39) | MAPTSLC22A16CES2CES1CYP1A2 | |
| Water SCHEMBL15994022 | 0.96 | MAPT (0.39) | MAPTSLC22A16CES2CES1CYP1A2 | |
| Fluoride Ion SCHEMBL15993970 | 0.96 | MAPT (0.39) | MAPTSLC22A16CES2CES1CYP1A2 | |
| Hydrochloric Acid SCHEMBL316715 | 0.96 | MAPT (0.43) | MAPTSLC22A16CES2CES1CYP1A2 | |
| Hydrochloric Acid SCHEMBL19025641 | 0.96 | MAPT (0.39) | MAPTSLC22A16CES2CES1CYP1A2 | |
| Glycerin SCHEMBL3308566 | 0.87 | SLC22A16 (0.41) | MAPTSLC22A16CYP1A2MEN1LMNA | |
| SCHEMBL5582502 | 0.86 | MAPT (0.44) | MAPTSLC22A16CYP1A2TSHRMEN1 | |
| SCHEMBL9631685 | 0.83 | CES2 (0.48) | MAPTCES2CYP1A2MAPK1TSHR | |
| Bromide SCHEMBL21643593 | 0.82 | MAPT (0.41) | MAPTSLC22A16CYP1A2TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113025000-A | PEDOT (Poly ethylene terephthalate) PSS (Poly styrene sulfonate) material, processing method and quantum dot light-emitting diode | TCL集团股份有限公司 | 2021-06-25 | — | — | CN | claimed |
| JP-1231887-A | — | — | None | — | — | JP | disclosed |
| WO-2025262036-A1 | METHOD OF MANUFACTURING A PHARMACEUTICAL COMPOSITION | RNASSIST LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-3827241-B1 | DISSOCIATION OF BIOLOGICAL SAMPLES | GOLDSBOROUGH ANDREW SIMON (FR) | 2024-03-13 | — | — | EP | disclosed |
| US-20240027309-A1 | SIMPLE FIXATION AND STABILISATION | RNASSIST LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20230220313-A1 | COMPOSITION AND METHOD FOR INACTIVATING A VIRUS | RNASSIST LTD. (GB) | 2023-07-13 | — | — | US | disclosed |
| EP-4133062-A1 | COMPOSITION AND METHOD FOR INACTIVATING A VIRUS | Rnassist Limited (GB) | 2023-02-15 | — | — | EP | disclosed |
| US-20210231538-A1 | DISSOCIATION OF BIOLOGICAL SAMPLES | GOLDSBOROUGH ANDREW SIMON (FR) | 2021-07-29 | — | — | US | disclosed |
| CN-113025000-A | PEDOT (Poly ethylene terephthalate) PSS (Poly styrene sulfonate) material, processing method and quantum dot light-emitting diode | TCL集团股份有限公司 | 2021-06-25 | — | — | CN | disclosed |
| EP-3827241-A1 | DISSOCIATION OF BIOLOGICAL SAMPLES | Goldsborough, Andrew Simon (FR) | 2021-06-02 | — | — | EP | disclosed |
| US-9696247-B2 | Sample fixation and stabilisation | RNASSIST LTD. (GB) | 2017-07-04 | — | — | US | disclosed |
| EP-2961268-A1 | SAMPLE FIXATION AND STABILISATION | Goldsborough, Andrew Simon (FR) | 2016-01-06 | — | — | EP | disclosed |
| US-20140295404-A1 | SAMPLE FIXATION AND STABILISATION | RNASSIST LTD. (GB) | 2014-10-02 | — | — | US | disclosed |
| WO-2014131906-A1 | SAMPLE FIXATION AND STABILISATION | GOLDSBOROUGH ANDREW SIMON (FR) | 2014-09-04 | — | — | WO | disclosed |
| EP-0518352-B1 | Process for forming super high-contrast negative images and silver halide photographic material and developer being used therefor | DAINIPPON INK & CHEMICALS (JP) | 1998-04-22 | — | — | EP | disclosed |
| US-5460919-A | Process of forming super high-contrast negative images and silver halide photographic material and developer being used therefor | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1995-10-24 | — | — | US | disclosed |
| US-5372911-A | Support having one or more hydrophilic colloidal layers, at least one layer contains pyridinium salt or derivative, quinolinium salt or derivative, or isoquinolinium salt or derivative | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1994-12-13 | — | — | US | disclosed |
| EP-0518352-A1 | Process for forming super high-contrast negative images and silver halide photographic material and developer being used therefor | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1992-12-16 | — | — | EP | disclosed |
| JP-H01231887-A | PREPARATION OF PROTEIN | DR KARL THOMAE GMBH | 1989-09-18 | — | — | JP | disclosed |
| EP-0315782-A2 | Method for the production of proteins | Dr. Karl Thomae GmbH (DE) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240027309-A1 | SIMPLE FIXATION AND STABILISATION | EWSR1, FOSB, PAXBP1 | CHRM2 4753/4885CHRM4 4697/4885CHRM1 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.